Introduction to Stem Cell Therapy for Acute Toxic Hepatitis
Acute toxic hepatitis (ATH) is a severe liver disease characterized by rapid-onset inflammation and liver cell damage caused by exposure to hepatotoxic agents. A pesar de los avances en la atención médica, the treatment options for ATH remain limited, and liver transplantation is often the only life-saving intervention. Terapia con células madre has emerged as a promising therapeutic approach for ATH, Ofrece el potencial de regenerar el tejido hepático dañado y restaurar la función hepática..
Pathogenesis of Acute Toxic Hepatitis and Role of Stem Cells
ATH is triggered by various hepatotoxins, including drugs, toxinas, and environmental pollutants. These agents induce oxidative stress, disfunción mitocondrial, and apoptosis in hepatocytes, leading to liver inflammation and necrosis. Células madre, particularmente células madre mesenquimales (MSC) y células madre hepáticas (HSC), have shown promise in mitigating these pathological processes. MSCs possess anti-inflammatory and immunomodulatory properties that can suppress liver inflammation and promote tissue repair. HSC, por otro lado, have the capacity to differentiate into functional hepatocytes, potentially replacing damaged liver cells and restoring liver function.
Preclinical Animal Studies of Stem Cell Therapy for Hepatitis
Preclinical studies in animal models of ATH have demonstrated the efficacy of terapia con células madre. In animal models of acetaminophen-induced liver injury, administration of MSCs has been shown to reduce liver inflammation, promover la regeneración de hepatocitos, y mejorar la función hepática. Similarmente, studies using HSCs have shown promising results, with transplanted HSCs successfully differentiating into functional hepatocytes and restoring liver function. These preclinical findings provide a strong rationale for further investigation of terapia con células madre in the treatment of ATH.
